Preventing intimal thickening of vein grafts in vein artery bypass using STAT-3 siRNA
详细信息 查看全文
- 作者：Jiangbin Sun (1) (2)
Jinhua Zheng (2)
Kaitelynne H Ling (3)
Keyan Zhao (1)
Zhongshang Xie (1)
Bo Li (1)
Tiance Wang (1)
Zhicheng Zhu (1)
Amit N Patel (4)
Weiping Min (3) (5)
Kexiang Liu (1)
Xiufen Zheng (3) (5) (6) - 关键词：STAT ; 3 ; siRNA ; vascular smooth muscle cells (VSMCs) ; intimal thickening
- 刊名：Journal of Translational Medicine
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：10
- 期：1
- 全文大小：956KB
- 参考文献：1. Pereira CE, Albers M, Romiti M, Brochado-Neto FC, Pereira CA: Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. / J Vasc Surg 2006, 44:510-17. CrossRef
2. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, / et al.: Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. / JAMA 2005, 294:2446-454. CrossRef
3. Cho KR, Kim JS, Choi JS, Kim KB: Serial angiographic follow-up of grafts one year and five years after coronary artery bypass surgery. / Eur J Cardiothorac Surg 2006, 29:511-16. CrossRef
4. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, / et al.: Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. / J Vasc Surg 2006, 43:742-51. discussion 751 CrossRef
5. Shah PJ, Gordon I, Fuller J, Seevanayagam S, Rosalion A, Tatoulis J, Raman JS, Buxton BF: Factors affecting saphenous vein graft patency: clinical and angiographic study in 1402 symptomatic patients operated on between 1977 and 1999. / J Thorac Cardiovasc Surg 2003, 126:1972-977. CrossRef
6. Wallitt EJ, Jevon M, Hornick PI: Therapeutics of vein graft intimal hyperplasia: 100 years on. / Ann Thorac Surg 2007, 84:317-23. CrossRef
7. Zwolak RM, Kirkman TR, Clowes AW: Atherosclerosis in rabbit vein grafts. / Arteriosclerosis 1989, 9:374-79. CrossRef
8. Parang P, Arora R: Coronary vein graft disease: pathogenesis and prevention. / Can J Cardiol 2009, 25:e57-2. CrossRef
9. Dilley RJ, McGeachie JK, Tennant M: The role of cell proliferation and migration in the development of a neo-intimal layer in veins grafted into arteries, in rats. / Cell Tissue Res 1992, 269:281-87. CrossRef
10. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK: A cascade model for restenosis. A special case of atherosclerosis progression. / Circulation 1992, 86:III47-2.
11. Muto A, Model L, Ziegler K, Eghbalieh SD, Dardik A: Mechanisms of vein graft adaptation to the arterial circulation: insights into the neointimal algorithm and management strategies. / Circ J 2010, 74:1501-512. CrossRef
12. Yellaturu CR, Rao GN: Cytosolic phospholipase A2 is an effector of Jak/STAT signaling and is involved in platelet-derived growth factor BB-induced growth in vascular smooth muscle cells. / J Biol Chem 2003, 278:9986-992. CrossRef
13. Neeli I, Liu Z, Dronadula N, Ma ZA, Rao GN: An essential role of the Jak-2/STAT-3/cytosolic phospholipase A(2) axis in platelet-derived growth factor BB-induced vascular smooth muscle cell motility. / J Biol Chem 2004, 279:46122-6128. CrossRef
14. Dronadula N, Liu Z, Wang C, Cao H, Rao GN: STAT-3-dependent cytosolic phospholipase A2 expression is required for thrombin-induced vascular smooth muscle cell motility. / J Biol Chem 2005, 280:3112-120. CrossRef
15. Qing M, Nimmesgern A, Heinrich PC, Schumacher K, Vazquez-Jimenez JF, Hess J, von Bernuth G, Seghaye MC: Intrahepatic synthesis of tumor necrosis factor-alpha related to cardiac surgery is inhibited by interleukin-10 via the Janus kinase (Jak)/signal transducers and activator of transcription (STAT) pathway. / Crit Care Med 2003, 31:2769-775. CrossRef
16. Wang TH, Xiang QL, Chen JW, Pan H, Cui YH: Raloxifene plus 17beta-estradiol inhibits proliferation of primary cultured vascular smooth muscle cells and human mammary endothelial cells via the janus kinase/signal transducer and activator of transcription3 cascade. / Eur J Pharmacol 2007, 561:7-3. CrossRef
17. Tang M, Zhang Z, Fu JY, Ning JM, Wang YD: [Stat 3 signal transduction pathway correlates with proliferation of vascular smooth muscle cells of rats]. / Zhonghua Xin Xue Guan Bing Za Zhi 2005, 33:832-35.
18. Marrero MB, Schieffer B, Li B, Sun J, Harp JB, Ling BN: Role of Janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation. / J Biol Chem 1997, 272:24684-4690. CrossRef
19. Kakisis JD, Pradhan S, Cordova A, Liapis CD, Sumpio BE: The role of STAT-3 in the mediation of smooth muscle cell response to cyclic strain. / Int J Biochem Cell Biol 2005, 37:1396-406. CrossRef
20. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ: Recombinant gene expression in vivo within endothelial cells of the arterial wall. / Science 1989, 244:1342-344. CrossRef
21. Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC: Implantation of vascular grafts lined with genetically modified endothelial cells. / Science 1989, 244:1344-346. CrossRef
22. Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF: Seeding of intravascular stents with genetically engineered endothelial cells. / Circulation 1989, 80:1347-353. CrossRef
23. Kallenbach K, Salcher R, Heim A, Karck M, Mignatti P, Haverich A: Inhibition of smooth muscle cell migration and neointima formation in vein grafts by overexpression of matrix metalloproteinase-3. / J Vasc Surg 2009, 49:750-58. CrossRef
24. Sugimoto M, Yamanouchi D, Komori K: Therapeutic approach against intimal hyperplasia of vein grafts through endothelial nitric oxide synthase/nitric oxide (eNOS/NO) and the Rho/Rho-kinase pathway. / Surg Today 2009, 39:459-65. CrossRef
25. Bhardwaj S, Roy H, Yla-Herttuala S: Gene therapy to prevent occlusion of venous bypass grafts. / Expert Rev Cardiovasc Ther 2008, 6:641-52. CrossRef
26. Aubart FC, Sassi Y, Coulombe A, Mougenot N, Vrignaud C, Leprince P, Lechat P, Lompre AM, Hulot JS: RNA interference targeting STIM1 suppresses vascular smooth muscle cell proliferation and neointima formation in the rat. / Mol Ther 2009, 17:455-62. CrossRef
27. Qu Y, Shi X, Zhang H, Sun W, Han S, Yu C, Li J: VCAM-1 siRNA reduces neointimal formation after surgical mechanical injury of the rat carotid artery. / J Vasc Surg 2009, 50:1452-458. CrossRef
28. Karshovska E, Zernecke A, Sevilmis G, Millet A, Hristov M, Cohen CD, Schmid H, Krotz F, Sohn HY, Klauss V, / et al.: Expression of HIF-1alpha in injured arteries controls SDF-1alpha mediated neointima formation in apolipoprotein E deficient mice. / Arterioscler Thromb Vasc Biol 2007, 27:2540-547. CrossRef
29. Wang L, Zheng J, Bai X, Liu B, Liu CJ, Xu Q, Zhu Y, Wang N, Kong W, Wang X: ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. / Circ Res 2009, 104:688-98. CrossRef
30. Wang J, Liu K, Shen L, Wu H, Jing H: Small interfering RNA to c-myc inhibits vein graft restenosis in a rat vein graft model. / J Surg Res 2011, 169:e85-1. CrossRef
31. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT: Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. / Proc Natl Acad Sci USA 1997, 94:14483-4488. CrossRef
32. Dobrin PB, Littooy FN, Endean ED: Mechanical factors predisposing to intimal hyperplasia and medial thickening in autogenous vein grafts. / Surgery 1989, 105:393-00.
33. Cai X: Regulation of smooth muscle cells in development and vascular disease: current therapeutic strategies. / Expert Rev Cardiovasc Ther 2006, 4:789-00. CrossRef
34. Chiu JJ, Usami S, Chien S: Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis. / Ann Med 2009, 41:19-8. CrossRef
35. George SJ, Baker AH, Angelini GD, Newby AC: Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. / Gene Ther 1998, 5:1552-560. CrossRef
36. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH: Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. / Hum Gene Ther 1998, 9:867-77. CrossRef
37. Touyz RM, He G, Deng LY, Schiffrin EL: Role of extracellular signal-regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance arteries. / Circulation 1999, 99:392-99.
38. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. / Science 1994, 265:781-84. CrossRef
39. D S, S JT: Src: more than the sum of its parts. / Trends Cell Biol 1997, 7:215-17. CrossRef
40. George SJ, Angelini GD, Capogrossi MC, Baker AH: Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. / Gene Ther 2001, 8:668-76. CrossRef
41. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. / Proc Natl Acad Sci USA 1993, 90:8474-478. CrossRef
42. Zwolak RM, Adams MC, Clowes AW: Kinetics of vein graft hyperplasia: association with tangential stress. / J Vasc Surg 1987, 5:126-36.
43. Yamamura S, Okadome K, Onohara T, Komori K, Sugimachi K: Blood flow and kinetics of smooth muscle cell proliferation in canine autogenous vein grafts: in vivo BrdU incorporation. / J Surg Res 1994, 56:155-61. CrossRef
44. Bromberg J, Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. / Oncogene 2000, 19:2468-473. CrossRef
45. Shibata R, Kai H, Seki Y, Kato S, Wada Y, Hanakawa Y, Hashimoto K, Yoshimura A, Imaizumi T: Inhibition of STAT3 prevents neointima formation by inhibiting proliferation and promoting apoptosis of neointimal smooth muscle cells. / Hum Gene Ther 2003, 14:601-10. CrossRef
46. Yang J, Jiang H, Chen SS, Chen J, Li WQ, Xu SK, Wang JC: Lentivirus-mediated RNAi targeting CREB binding protein attenuates neointimal formation and promotes re-endothelialization in balloon injured rat carotid artery. / Cell Physiol Biochem 2010, 26:441-48. CrossRef
47. San Juan A, Bala M, Hlawaty H, Portes P, Vranckx R, Feldman LJ, Letourneur D: Development of a functionalized polymer for stent coating in the arterial delivery of small interfering RNA. / Biomacromolecules 2009, 10:3074-080. CrossRef - 作者单位：Jiangbin Sun (1) (2)
Jinhua Zheng (2)
Kaitelynne H Ling (3)
Keyan Zhao (1)
Zhongshang Xie (1)
Bo Li (1)
Tiance Wang (1)
Zhicheng Zhu (1)
Amit N Patel (4)
Weiping Min (3) (5)
Kexiang Liu (1)
Xiufen Zheng (3) (5) (6)
1. Department of Cardiovascular Surgery, The Second Hospital, Jilin University, Chang Chun, China
2. The Fourth Hospital of Harbin Medical University, Harbin, China
3. University of Western Ontario, London, Ontario, Canada
4. Division of Surgery, University of Utah, Salt Lake City, UT, 84132, USA
5. Lawson Institute of Health Research, London, Ontario, Canada
6. Xinjiang University, Urmuqi, China
文摘
Background Proliferation and migration of vascular smooth muscle cells (VSMCs) play a key role in neointimal formation which leads to restenosis of vein graft in venous bypass. STAT-3 is a transcription factor associated with cell proliferation. We hypothesized that silencing of STAT-3 by siRNA will inhibit proliferation of VSMCs and attenuate intimal thickening. Methods Rat VSMCs were isolated and cultured in vitro by applying tissue piece inoculation methods. VSMCs were transfected with STAT 3 siRNA using lipofectamine 2000. In vitro proliferation of VSMC was quantified by the MTT assay, while in vivo assessment was performed in a venous transplantation model. In vivo delivery of STAT-3 siRNA plasmid or scramble plasmid was performed by admixing with liposomes 2000 and transfected into the vein graft by bioprotein gel applied onto the adventitia. Rat jugular vein-carotid artery bypass was performed. On day 3 and7 after grafting, the vein grafts were extracted, and analyzed morphologically by haematoxylin eosin (H&E), and assessed by immunohistochemistry for expression of Ki-67 and proliferating cell nuclear antigen (PCNA). Western-blot and reverse transcriptase polymerase chain reaction (RT-PCR) were used to detect the protein and mRNA expression in vivo and in vitro. Cell apoptosis in vein grafts was detected by TUNEL assay. Results MTT assay shows that the proliferation of VSMCs in the STAT-3 siRNA treated group was inhibited. On day 7 after operation, a reduced number of Ki-67 and PCNA positive cells were observed in the neointima of the vein graft in the STAT-3 siRNA treated group as compared to the scramble control. The PCNA index in the control group (31.3 ± 4.7) was higher than that in the STAT-3 siRNA treated group (23.3 ± 2.8) (P < 0.05) on 7d. The neointima in the experimental group(0.45 ± 0.04 μm) was thinner than that in the control group(0.86 ± 0.05 μm) (P < 0.05).Compared with the control group, the protein and mRNA levels in the experimental group in vivo and in vitro decreased significantly. Down regulation of STAT-3 with siRNA resulted in a reduced expression of Bcl-2 and cyclin D1. However, apoptotic cells were not obviously found in all grafts on day 3 and 7 post surgery. Conclusions The STAT-3 siRNA can inhibit the proliferation of VSMCs in vivo and in vitro and attenuate neointimal formation.